A look at MNCs with clinical trials that could be disrupted by the coronavirus outbreak

Almost all major biopharma MNCs are conducting clinical trials in China that could face disruptions as the outbreak of 2019-nCoV acute respiratory disease continues to unfold. An analysis of MNCs most active in the region finds Roche could be hit the hardest.

According to ClinicalTrials.gov, at least 22 MNCs are sponsoring interventional trials in China, and 18 of those companies have trial sites in Wuhan, the epicenter of the viral outbreak. The analysis included studies that are recruiting, enrolling by invitation or active but not recruiting...